One price at every standard dose
Both flat rates are printed with the sentence that the price is the same at every standard dose level the clinician prescribes. That is the commitment that matters in this category, because GLP-1 dosing steps up and a per-strength price turns a quoted figure into an opening bid.
Alongside the two standard rates, a separate microdose programme is priced with a stated milligram ceiling. Pricing the low-dose lane separately is the honest alternative to quoting the microdose rate and selling a standard dose.
The molecule the microdose card does not name
The microdose card gives a starting price and a dosing ceiling and never says which drug it is. Twenty of the one hundred and fifty-eight sellers here put a figure beside a product they will only call a GLP-1, and this card is one of them, on a page whose other two cards name their molecules.
That is a smaller failure than a whole site that never names a drug, and it is still the one thing on this page a reader cannot resolve. We have recorded the row as an unnamed GLP-1 rather than assigning it to either molecule.
No membership, no teaser, and no state list
The page states no membership fees, no clinician fees, no teaser pricing, month to month, and separately that clinician care, follow-up messaging and shipping are included with no membership fee. Fifty-five of the one hundred and fifty-eight sellers here state that no membership applies.
No teaser pricing is worth isolating, because it is a promise about tomorrow rather than about today, and it is the promise that most of this batch quietly breaks with a countdown timer or a first-order code. This seller commits against both.
What is missing is everything about who and where. No compounding pharmacy is named, no clinician is named, and no service area is published beyond a statement that the prescribing clinician is licensed in the buyer's state. One hundred and fifteen of the one hundred and fifty-eight sellers here publish no service area at all. The operating company appears only in a footer copyright line.
Avono Health's published pricing
| Medication | Price | Verified |
|---|---|---|
| Semaglutide (compounded) | $219/moper month, stated as the same price at every standard dose level the clinician prescribes | September 2026source |
| Tirzepatide (compounded) | $299/moper month, stated as the same price at every standard dose level the clinician prescribes | September 2026source |
| Glp-1 (compounded) | $159/moper month, starting price, for a clinician-guided lower-dose programme; the card does not name which molecule the microdose lane uses | September 2026source |
compareglp may earn a commission when a reader signs up with a provider through a link on this site. 4 of the 158 providers reviewed here are paid partners today; the other 154 are not. See how this works.
See Avono Health's current price →Good fit if
- Buyers who want a flat rate that does not move with the dose, stated twice.
- Readers who want a written commitment against teaser pricing.
- People who want a lower-dose programme priced on its own terms.
- Anyone who would rather have their card authorised than charged during an intake.
Look elsewhere if
- Anyone considering the microdose lane who needs to know which drug it is.
- Readers who want the compounding pharmacy or a clinician named.
- Buyers who need a service-area list.
- People who want more identity disclosure than a footer copyright line.
How this review was verified
- Re-read the weight-management page on 6 September 2026, comparing the requested path to the effective path and running a nonsense path against the host in the same run.
- Recorded the microdose row as an unnamed GLP-1 rather than assigning it to a molecule the card does not name.
- Read the no-membership position from two separate statements on the page rather than from a single strapline, and recorded the no-teaser-pricing claim separately because it is a different kind of promise.
- Recorded the card-authorisation statement as published, since it describes when money moves rather than how much.
- Screened the operating entity and the brand name against FDA's live warning-letter record with a known letter as a positive control and a nonsense string as a negative control in the same pass. Neither returned a letter. Untitled letters are published separately and were not searched.